Lusis
Private Company
Funding information not available
Overview
Lusis Biosciences is a private, commercial-stage diagnostics company developing and manufacturing multiplex qPCR assays and instruments for infectious disease applications. The company leverages integrated development and manufacturing to offer a broad catalog of over 30 key products and hundreds of targets, which are used by over 10,000 laboratories across 160 countries. Its business model centers on providing affordable, high-performance molecular tools paired with dedicated customer support and field application services. Lusis operates under the philosophy of 'Innovation for All,' aiming to improve healthcare equity through accessible diagnostic solutions.
Technology Platform
Multiplex qPCR (quantitative Polymerase Chain Reaction) technology for the simultaneous detection of multiple pathogen targets. Integrated development and manufacturing of reagents and instruments.
Opportunities
Risk Factors
Competitive Landscape
Lusis competes in the crowded molecular diagnostics space against giants like Roche, Abbott, BioMérieux, and Qiagen, which offer comprehensive qPCR systems and tests. Its differentiation is based on a value proposition of affordability, a broad infectious disease menu, and dedicated customer service, targeting labs underserved by premium-priced market leaders.